Upadacitinib: A Convenient and Effective Alternative Treatment for Spondyloarthritis

By Danélia Botes

February 3, 2023

Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and/or Visual Analogue Scale (VAS) score to measure this. A cost comparison shows that upadacitinib costs about the same and provides similar health benefits as secukinumab and ixekizumab.

The update suggests considering upadacitinib as an alternative to the National Institute for Health and Care Excellence (NICE) recommended Interleukin (IL)-17 inhibitors. This is especially important if conventional therapy doesn’t control the condition well enough or if TNF-alpha inhibitors aren’t suitable or effective.

Clinical and patient experts highlighted the convenience of upadacitinib over IL-17 inhibitors owing to its oral administration.

Reference url

Recent Posts

Health Economics and Outcomes Research
                    

Health Economics and Outcomes Research in Global Healthcare

Explore how Health Economics and Outcomes Research (HEOR) is shaping the future of global healthcare. Read our latest article to learn more about the strategic approaches being adopted to maximise the impact of HEOR. #Healthcare #HEOR #GlobalHealthcare 🌍🩺📊 Read more here

             

Data Science Hub in Kenya: Innovating Health Equity

🌍 Exciting news! 🎉 Aga Khan University and the University of Michigan are joining forces to establish a data science hub in Kenya 🇰🇪. Using AI and machine learning, they aim to improve health equity and care delivery 🏥. #DataScience #AI #HealthEquity #Collaboration

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.